OncoMatch

OncoMatch/Clinical Trials/NCT07740239

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

Is NCT07740239 recruiting? Yes, currently enrolling (Sep 2026).

RecruitingTampere University HospitalNCT07740239Data as of Sep 2026Location: Finland

The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Non-Small Cell Lung Carcinoma

Small Cell Lung Cancer

Demographics

Ages ≥ 60
Male only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07740239 currently recruiting?

Yes, this trial is currently recruiting patients.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify